<unk>  is indicated for people with Pompe disease (GAA deficiency). In 2014 the U.S. Food and Drug Administration announced the approval of<unk>  for treatment of people with infantile-onset Pompe disease, including people who are less than eight years of age. In addition, the Risk Evaluation and Mitigation Strategy (REMS) is being eliminated.
Alglucosidase alfa
Avalglucosidase alfa
Voglibose
Glucuronide
Vestronidase alfa
Icodextrin
Acemannan
Dasiglucagon